Olutasidenib
Olutasidenib, sold under the brand name Rezlidhia, is an anticancer medication used to treat relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation.
≈ 1 min read
Olutasidenib. encyclopegia.org, snapshot enwiki-001338707943. /a/olutasidenib
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Olutasidenib, sold under the brand name Rezlidhia, is an anticancer medication used to treat relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation. Olutasidenib is an isocitrate dehydrogenase-1 (IDH1) inhibitor. It is taken by mouth.
The most common adverse reactions include nausea, fatigue/malaise, arthralgia, constipation, leukocytosis, dyspnea, fever, rash, mucositis, diarrhea, and transaminitis. Olutasidenib was approved for medical use in the United States in December 2022, based on the phase 1 results of a phase 1/2 trial.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1338707943 under CC BY-SA 4.0; modifications have been made.